A Meta-Analysis of the Impact of Resveratrol Supplementation on Markers of Renal Function and Blood Pressure in Type 2 Diabetic Patients on Hypoglycemic Therapy.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, c1995-

Dietary Supplements*; Biomarkers/*analysis ; Cardiovascular Diseases/*prevention & control ; Diabetes Mellitus, Type 2/*drug therapy ; Hypoglycemic Agents/*administration & dosage ; Kidney Diseases/*prevention & control ; Resveratrol/*therapeutic use; Antioxidants/therapeutic use ; Blood Pressure ; Drug Therapy, Combination ; Humans ; Kidney Function Tests

Evidence on the beneficial effects of resveratrol supplementation on cardiovascular disease-related profiles in patients with type 2 diabetes (T2D) is conflicting, while its impact on renal function and blood pressure measurements remains to be established in these patients. The current meta-analysis included randomized controlled trials (RCTs) reporting on the impact of resveratrol supplementation on markers of renal function and blood pressure in patients with T2D on hypoglycemic medication. Electronic databases such as MEDLINE, Cochrane Library, Scopus, and EMBASE were searched for eligible studies from inception up to June 2020. The random and fixed effects model was used in the meta-analysis. A total of five RCTs met the inclusion criteria and involved 388 participants with T2D. Notably, most of the participants were on metformin therapy, or metformin in combination with other hypoglycemic drugs such as insulin and glibenclamide. Pooled estimates showed that resveratrol supplementation in patients with T2D lowered the levels of fasting glucose (SMD: -0.06 [95% CI: -0.24, 0.12]; I ² = 4%, p = 0.39) and insulin (SMD: -0.08 [95% CI: -0.50, 0.34], I ² = 73%, p = 0.002) when compared to those on placebo. In addition, supplementation significantly lowered systolic blood pressure (SMD: -5.77 [95% CI: -8.61, -2.93], I ² = 66%, p = 0.02) in these patients. Although resveratrol supplementation did not affect creatinine or urea levels, it reduced the total protein content (SMD: -0.19 [95% CI: -0.36, -0.02]; I ² = 91%, p = 0.001). In all, resveratrol supplementation in hypoglycemic therapy improves glucose control and lowers blood pressure; however, additional evidence is necessary to confirm its effect on renal function in patients with T2D.

Stat Med. 2002 Jun 15;21(11):1539-58. (PMID: 12111919)
World J Diabetes. 2017 Apr 15;8(4):120-129. (PMID: 28465788)
Diabetologia. 2017 Sep;60(9):1577-1585. (PMID: 28776086)
Pharmacol Res. 2016 Sep;111:896-905. (PMID: 27520400)
Diabetologia. 2017 Sep;60(9):1586-1593. (PMID: 28770321)
Drug Metab Rev. 2012 Aug;44(3):253-65. (PMID: 22788578)
Nutrients. 2010 Jun;2(6):611-25. (PMID: 22254045)
Diabetes Spectr. 2015 Aug;28(3):175-80. (PMID: 26300610)
Diabetes. 2017 Feb;66(2):241-255. (PMID: 27980006)
J Investig Med. 2016 Aug;64(6):1082-6. (PMID: 27194746)
Int J Obes (Lond). 2008 May;32 Suppl 2:S21-4. (PMID: 18469836)
Clin Nutr. 2015 Feb;34(1):27-34. (PMID: 24731650)
Clin Immunol. 2020 Jan;210:108313. (PMID: 31765833)
Nat Prod Rep. 2021 Jul 21;38(7):1282-1329. (PMID: 33351014)
Rev Esp Cardiol. 2002 May;55(5):528-35. (PMID: 12015934)
Obesity (Silver Spring). 2019 Jan;27(1):94-102. (PMID: 30569644)
Lancet Diabetes Endocrinol. 2013 Oct;1(2):106-14. (PMID: 24622316)
Food Funct. 2019 Oct 16;10(10):6227-6243. (PMID: 31591634)
Lancet. 1975 Jan 4;1(7897):14-6. (PMID: 46337)
Int J Sport Nutr Exerc Metab. 2014 Feb;24(1):2-13. (PMID: 23918588)
Nutrients. 2020 Mar 11;12(3):. (PMID: 32168855)
Diabetes Metab Syndr Obes. 2014 Dec 04;7:587-91. (PMID: 25506234)
J Epidemiol Community Health. 1998 Jun;52(6):377-84. (PMID: 9764259)
Acta Diabetol. 2018 Apr;55(4):341-353. (PMID: 29357033)
Endocrinology. 2011 Dec;152(12):4610-9. (PMID: 21971158)
Nutrients. 2019 Jul 17;11(7):. (PMID: 31319485)
Eur J Clin Nutr. 2009 Nov;63 Suppl 4:S226-38. (PMID: 19888276)
J Am Coll Nutr. 2014;33(2):176-82. (PMID: 24724775)
Physiol Res. 2018 Nov 14;67(5):813-818. (PMID: 30044119)
Arch Med Sci. 2014 May 12;10(2):336-44. (PMID: 24904670)
Crit Rev Food Sci Nutr. 2019;59(10):1605-1618. (PMID: 29359958)
Nutr Res. 2012 Jul;32(7):537-41. (PMID: 22901562)
Diabetes Care. 2016 Dec;39(12):2211-2217. (PMID: 27852684)
Evid Based Complement Alternat Med. 2013;2013:851267. (PMID: 24073011)
Diabetes Obes Metab. 2020 Feb;22(2):212-221. (PMID: 31595635)
Oxid Med Cell Longev. 2013;2013:568093. (PMID: 24379901)
Nutr Metab Cardiovasc Dis. 2016 May;26(5):393-9. (PMID: 27105868)
Nutr Metab (Lond). 2017 Sep 22;14:60. (PMID: 29018489)
J Grad Med Educ. 2012 Sep;4(3):279-82. (PMID: 23997866)
Int J Mol Sci. 2019 Dec 24;21(1):. (PMID: 31878222)
J Alzheimers Dis. 2019;71(3):945-956. (PMID: 31450493)
Biochim Biophys Acta. 2015 Jun;1852(6):1071-113. (PMID: 25652123)
Diabetes Metab Syndr Obes. 2013;6:93-102. (PMID: 23430507)
Oxid Med Cell Longev. 2013;2013:963217. (PMID: 24489988)
Biometrics. 1977 Mar;33(1):159-74. (PMID: 843571)

D43 TW010131 United States TW FIC NIH HHS

Keywords: blood pressure; diabetic complications; hypoglycemic therapy; metabolic syndrome; metformin; polyphenols; renal function; resveratrol; type 2 diabetes

0 (Antioxidants)
0 (Biomarkers)
0 (Hypoglycemic Agents)
Q369O8926L (Resveratrol)

Date Created: 20201203 Date Completed: 20210408 Latest Revision: 20240331

20240331

PMC7730696

10.3390/molecules25235645

33266114